Skip to main content
. Author manuscript; available in PMC: 2011 Feb 17.
Published in final edited form as: Adv Drug Deliv Rev. 2009 Nov 14;62(2):122–149. doi: 10.1016/j.addr.2009.10.004

Fig. 9.

Fig. 9

Efficacy of combination chemotherapy and photodynamic therapy of OVCAR-3 xenografts in nude mice with non-targeted and OV-TL16 antibody-targeted HPMA copolymer conjugates. Therapeutic efficacy of combination therapy of HPMA copolymer-bound Mce6 (P(GFLG)–Mce6) and DOX (P(GFLG)–DOX) targeted with OV-TL 16 antibodies toward OVCAR-3 xenografts was compared to non-treated xenografts and non-targeted combination chemotherapy and photodynamic therapy. Equivalent doses of targeted combination therapy enhanced the tumor-suppressive effect as compared to non-targeted combination therapy. Dose administered: 2.2 mg/kg DOX equivalent and 1.5 mg/kg Mce6 equivalent. Irradiation for photodynamic therapy: 650 nm, 200 mW/cm2 18 h after administration [83, unpublished].